Synthesis of novel 3,5-disubstituted-2-oxindole derivatives as antitumor agents against human nonsmall cell lung cancer

ACS Medicinal Chemistry Letters

Volumn 4, Issue 12, 2013, Pages 1137-1141

  Nesi, Giulia ^a   Sestito, Simona ^a,b   Mey, Valentina ^a   Ricciardi, Simona ^a   Falasca, Marco ^b   Danesi, Romano ^a   Lapucci, Annalina ^a   Breschi, Maria C ^a   Fogli, Stefano ^a   Rapposelli, Simona ^a  

^a UNIVERSITY OF PISA   (Italy)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Antiproliferative activity; cell cycle; nonsmall cell lung cancer; oxindole; PDK1 Akt inhibitors

Indexed keywords

ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR;

AMINO ACID SEQUENCE; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CELL DEATH; CELL PROLIFERATION; CELL SURVIVAL; DRUG SYNTHESIS; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; IN VITRO STUDY; LUNG NON SMALL CELL CANCER; MORPHOLOGY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

EID: 84890545618     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml400162g     Document Type: Article

References (30)

1. Gadgeel, S. M.; Wozniak, A. Preclinical rationale for PI3K/Akt/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer Clin. Lung Cancer 2013, 14, 322-332
2. Laplante, M.; Sabatini, D. M. mTOR signaling in growth control and disease Cell 2012, 149, 274-293
3. Balsara, B. R.; Pei, J.; Mitsuuchi, Y.; Page, R.; Klein-Szanto, A.; Wang, H.; Unger, M.; Testa, J. R. Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions Carcinogenesis 2004, 25, 2053-2059
4. Oki, E.; Baba, H.; Tokunaga, E.; Nakamura, T.; Ueda, N.; Futatsugi, M.; Mashino, K.; Yamamoto, M.; Ikebe, M.; Kakeji, Y.; Maehara, Y. Akt phosphorylation associates with LOH of PTEN and leads to chemoresistance for gastric cancer Int. J. Cancer 2005, 117, 376-380
5. Carden, C. P.; Stewart, A.; Thavasu, P.; Kipps, E.; Pope, L.; Crespo, M.; Miranda, S.; Attard, G.; Garrett, M. D.; Clarke, P. A.; Workman, P.; de Bono, J. S.; Gore, M.; Kaye, S. B.; Banerji, U. The association of PI3 kinase signaling and chemoresistance in advanced ovarian cancer Mol. Cancer Ther. 2012, 11, 1609-1617
6. Janmaat, M. L.; Kruyt, F. A. E.; Rodriguez, J. A.; Giaccone, G. Response to epidermal growth factor receptor inhibitors in non- small cell lung cancer cells: Limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways Clin. Cancer Res. 2003, 9, 2316-2326
7. Altomare, D. A.; Testa, J. R. Perturbations of the AKT signaling pathway in human cancer Oncogene 2005, 24, 7455-7464
8. Cheng, J. Q.; Lindsley, C. W.; Cheng, G. Z.; Yang, H.; Nicosia, S. V. The Akt/PKB pathway: Molecular target for cancer drug discovery Oncogene 2005, 24, 7482-7492
9. Cardone, M. H.; Roy, N.; Stennicke, H. R.; Salvesen, G. S.; Franke, T. F.; Stanbridge, E.; Frisch, S.; Reed, J. C. Regulation of cell death protease caspase-9 by phosphorylation Science 1998, 282, 1318-1321
10. Datta, S. R.; Dudek, H.; Tao, X.; Masters, S.; Fu, H.; Gotoh, Y.; Greenberg, M. E. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery Cell 1997, 91, 231-241
11. Brunet, A.; Bonni, A.; Zigmond, M. J.; Lin, M. Z.; Juo, P.; Hu, L. S.; Anderson, M. J.; Arden, K. C.; Blenis, J.; Greenberg, M. E. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor Cell 1999, 96, 857-868
12. Lv, K.; Wang, L. L.; Zhou, X. B.; Liu, M. L.; Liu, H. Y.; Zheng, Z. B.; Li, S. Synthesis and in vitro antitumor activity of 1-(3-dimethylamino)propyl indolin-2-one derivatives Med. Chem. Res. 2013, 2, 1723-1729
13. Islam, I.; Bryant, J.; Chou, Y. L.; Kochanny, M. J.; Lee, W.; Phillips, G. B.; Yu, H.; Adler, M.; Whitlow, M.; Ho, E.; Lentz, D.; Polokoff, M. A.; Subramanyam, B.; Wu, J. M.; Zhu, D.; Feldman, R. I.; Arnaiz, D. O. Indolinone based phosphoinositide-dependent kinase-1 (PDK1) inhibitors. Part 1: Design, synthesis and biological activity Bioorg. Med. Chem. Lett. 2007, 17, 3814-3818
14. Islam, I.; Brown, G.; Bryant, J.; Hrvatin, P.; Kochanny, M. J.; Phillips, G. B.; Yuan, S.; Adler, M.; Whitlow, M.; Lentz, D.; Polokoff, M. A.; Wu, J.; Shen, J.; Walters, J.; Ho, E.; Subramanyam, B.; Zhu, D.; Feldman, R. I.; Arnaiz, D. O. Indolinone based phosphoinositide-dependent kinase-1 (PDK1) inhibitors. Part 2: Optimization of BX-517 Bioorg. Med. Chem. Lett. 2007, 17, 3819-3825
15. Mohler, M. L.; Kang, G. S.; Hong, S. S.; Patil, R.; Kirichenko, O. V.; Li, W.; Rakov, I. M.; Geisert, E.; Miller, D. D. Discovery of antiglioma activity of biaryl 1,2,3,4-tetrahydroisoquinoline derivatives and conformationally flexible analogues J. Med. Chem. 2006, 49, 5845-5848
16. Lin, H. R.; Safo, M. K.; Abraham, D. J. Identification of a series of tetrahydroisoquinoline derivatives as potential therapeutic agents for breast cancer Bioorg. Med. Chem. Lett. 2007, 17, 2581-2589
17. Li, Y.; Zhang, H. B.; Huang, W. L.; Li, Y. M. Design and synthesis of tetrahydroisoquinoline derivatives as potential multidrug resistance reversal agents in cancer Bioorg. Med. Chem. Lett. 2008, 18, 3652-3655
18. Colabufo, N. A.; Berardi, F.; Perrone, R.; Rapposelli, S.; Digiacomo, M.; Vanni, M.; Balsamo, A. 2-[(3-Methoxyphenylethyl)phenoxy]-based ABCB1 inhibitors: Effect of different basic side-chains on their biological properties J. Med. Chem. 2008, 51, 7602-7613
19. Choquette, D.; Teffera, Y.; Polverino, A.; Harmange, J. C. Discovery of novel 1,2,3,4-tetrahydroisoquinolines and 3,4-dihydroisoquinoline-1(2H)-ones as potent and selective inhibitors of KDR: Synthesis, SAR, and pharmacokinetic properties Bioorg. Med. Chem. Lett. 2008, 18, 4054-4058
20. Arnaiz, D.; Bryant, J.; Chou, Y. L.; Feldman, R.; Hrvatin, P.; Islam, I.; Kochanny, M.; Lee, W.; Polokoff, M.; Yu, H.; Yuan, S. Indolinone Derivatives and Their Use in Treating Disease-States Such As Cancer. US 07105563, 2006.
21. Tang, F.; Shen, H.; Jin, Q.; Ding, L.; Yang, J.; Yin, X.; Lu, S. 3-Pyrrole-cyclohexylene-2-dihydro-indolinone Derivatives and Uses Thereof. WO2008067756, 2008.
22. Sun, L.; Tran, N.; Tang, F.; App, H.; Hirth, P.; McMahon, G.; Tang, C. Synthesis and biological evaluations of 3-substituted indolin-2-ones: A novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular receptor tyrosine kinases J. Med. Chem. 1998, 41, 2588-2603
23. Zou, Z. Q.; Zhang, X. H.; Wang, F.; Shen, Q. J.; Xu, J.; Zhang, L. N.; Xing, W. H.; Zhuo, R. J.; Li, D. A. Novel dual PI3Kalpha/mTOR inhibitor PI-103 with high antitumor activity in non-small cell lung cancer cells Int. J. Mol. Med. 2009, 24, 97-101
24. Henery, S.; George, T.; Hall, B.; Basiji, D.; Ortyn, W.; Morrissey, P. Quantitative image based apoptotic index measurement using multispectral imaging flow cytometry: A comparison with standard photometric methods Apoptosis 2008, 13, 1054-1063
25. Sun, H.; Lesche, R.; Li, D. M.; Liliental, J.; Zhang, H.; Gao, J.; Gavrilova, N.; Mueller, B.; Liu, X.; Wu, H. PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3,4,5,-trisphosphate and Akt/protein kinase B signaling pathway Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 6199-6204
26. Alessi, D. R.; James, S. R.; Downes, C. P.; Holmes, A. B.; Gaffney, P. R.; Reese, C. B.; Cohen, P. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha Curr. Biol. 1997, 7, 261-269
27. Nagashima, K.; Shumway, S. D.; Sathyanarayanan, S.; Chen, A. H. Genetic and pharmacological inhibition of PDK1 in cancer cells: Characterization of a selective allosteric kinase inhibitor J. Biol. Chem. 2011, 286, 6433-6448
28. Raimondi, C.; Chikh, A.; Wheeler, A. P.; Maffucci, T.; Falasca, M. A novel regulatory mechanism links PLCγ1 to PDK1 J. Cell. Sci. 2012, 125, 3153-3163
29. Amann, J.; Kalyankrishna, S.; Massion, P. P.; Ohm, J. E.; Girard, L.; Shigematsu, H.; Peyton, M.; Juroske, D.; Huang, Y.; Stuart, S. J.; Kim, Y. H.; Pollack, J. R.; Yanagisawa, K.; Gazdar, A.; Minna, J. D.; Kurie, J. M.; Carbone, D. P. Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer Cancer Res. 2005, 65, 226-235
30. Mukohara, T.; Engelman, J. A.; Hanna, N. H.; Yeap, B. Y.; Kobayashi, S.; Lindeman, N.; Halmos, B.; Pearlberg, J.; Tsuchihashi, Z.; Cantley, L. C.; Tenen, D. G.; Johnson, B. E.; Jänne, P. A. Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations J. Natl. Cancer Inst. 2005, 97, 1185-1194